Perseus SENOLYTIX

Perseus SENOLYTIX develops MitoXcel™ oncopeptides, a new class of cancer therapeutics targeting the inner mitochondrial membrane to selectively eliminate cancer cells through mitochondrial-mediated mechanisms

Biotech & Life Sciences

Sector

Seed

Stage

Biotechnology

Model

01Company Overview

Perseus SENOLYTIX develops MitoXcel™ oncopeptides, a new class of cancer therapeutics targeting the inner mitochondrial membrane to selectively eliminate cancer cells through mitochondrial-mediated mechanisms.

02Backed By1 investor

RCRapha Capital Management→

03Similar Companies